Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus ...

Second Quarter 2025 Results Key Financial Results Revenue: US$264.6m (up ...

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks. Read why ACAD stock is a buy.

NasdaqGS:ACAD 1 Year Share Price vs Fair Value Explore ACADIA Pharmaceuticals's Fair Values from the Community ...

Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

(ACAD) on Wednesday reported second-quarter net income of $26.7 million. The San Diego-based company said it had net income of 16 ...

ACADIA Pharmaceuticals (NASDAQ: ACAD) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates ...

ACADIA Pharmaceuticals shares are trading lower by 4.11% during Tuesday's session. The company appointed Catherine Owen Adams as CEO. The next correction is closer than you think. Find out how Tom ...

Acadia Pharmaceuticals (ACAD 14.48%) is having a strong session Tuesday. Specifically, the drugmaker's shares were up by a healthy 6.7% on moderate volume at 10:02 a.m. ET.